唐念中,杜贺,陈少萍,石秀英,叶忠,郑兴

• 1:解放军第411医院心血管内科
• 2:第二军医大学长海医院心血管内科

摘要(Abstract)：

目的探讨经皮冠状动脉介入治疗(PCI)术后依诺肝素抗凝治疗对临床事件的影响。方法连续入选2011年5月至2013年11月在长海医院、解放军第411医院行PCI术中未发生无复流和冠状动脉夹层等具有血栓高危因素并发症的患者700例,随机分为依诺肝素抗凝组和非抗凝组,对入选患者分别在住院期间、术后1个月、12个月时随访并记录主要不良心脑血管事件(MACCE)的发生情况。结果抗凝组与非抗凝组住院期间(2.0%比2.3%,P=0.790)、术后1个月(3.2%比3.5%,P=0.826)、术后12个月(6.4%比6.7%,P=0.869)MACCE的发生率比较,差异均无统计学意义。两组患者住院期间严重出血的发生率比较,差异无统计学意义(0.6%比0.3%,P=0.565);抗凝组小出血的发生率高于非抗凝组(27.9%比20.4%,P=0.022)。结论 PCI术后非抗凝组与抗凝组相比,未增加MACCE发生率,且降低了住院期间小出血并发症的发生率。PCI术中若未发生无复流和冠状动脉夹层等具有血栓高危因素的并发症时,可无需抗凝治疗。

关键词(KeyWords)： 经皮冠状动脉介入治疗;依诺肝素;主要不良心脑血管事件;出血

Abstract:

Keywords:

基金项目(Foundation): 上海市科委科研计划项目(10411954900)

作者(Author): 唐念中,杜贺,陈少萍,石秀英,叶忠,郑兴

参考文献(References)：

• [1]Braunwald E,Antman EM,Beasley JW,et al.ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—2002:summary article:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committe on the Management of Patients with Unstable Angina).J Am Coll Cardiol,2002,40:1366-1374.
• [2]Smith SC Jr,Feldman TE,Hirshfeld JW Jr,et al.ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).Circulation,2006,113:166-286.
• [3]Swanson N,Hogrefe K,Stephens Lloyd A,et al.Current perspectives on British use of adjunctive therapies during coronary interventions.Int J Cardiol,2001,79:119-125.
• [4]Gregorini L,Marco J,Fajadet J,et al.Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures.J Am Coll Cardiol,1997,29:13-20.
• [5]Wright RS,Anderson JL,Adams CD,et a1.2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction(updating the 2007 guideline):a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians,Society for Cardiovascular Angiography and Interventions,and Society of Thoracic Surgeons.J Am Coll Cardiol,2011,57:1920-1959.
• [6]Jneid H,Anderson JL,Wright RS,et a1.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011 focused update):a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2012,60:645-681.
• [7]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南(2012).中华心血管病杂志,2012,40:271-277.
• [8]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南(2009).中华心血管病杂志,2009,37:4-25.
• [9]Costa FM,Ferreira J,Aguiar C,et al.Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years.Eur Heart J,2012,33:2544-2550.
• [10]Karrillon GJ,Morice MC,Benveniste E,et al.Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by anti-platelet therapy.30-day clinical outcome of the French Multicenter Registry.Circulation,1996,94:1519-1527.
• [11]Harjai KJ,Stone GW,Grines CL,et al.Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoproteinⅡb/Ⅲa inhibitors.Am J Cardiol,2007,99:202-207.
• [12]Batchelor WB,Mahaffey KW,Berger PB,et al.A randomized,placebo-controlled trial of enoxaparin after high-risk coronary stenting:the ATLAST trial.J Am Coll Cardiol,2001,38:1608-1613.
• [13]Babapulle MN,Joseph L,Bélisle P,et al.A hierarchical Bayesian meta-analysis of randomised clinical trials of drugeluting stents.Lancet,2004,364:583-591.
• [14]Roiron C,Sanchez P,Bouzamondo A,et al.Drug eluting stents:an updated meta-analysis of randomized controlled trials.Heart,2006,92:641-649.
• [15]Feit F,Voeltz MD,Attubato MJ,et al.Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial.Am J Cardiol,2007,100:1364-1369.
• [16]Manoukian SV,Feit F,Mehran R,et al.Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes:an analysis from the ACUITY Trial.J Am Coll Cardiol,2007,49:1362-1368.
• [17]Kinnaird TD,Stabile E,Mintz GS,et al.Incidence,predictors,and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions.Am J Cardiol,2003,92:930-935.
• [18]陈伟翔,郭素峡,羊镇宇,等.血小板功能检测与个体化抗血小板治疗.中国介入心脏病学杂志,2014,22:660-663.
• [19]Eikelboom JW,Mehta SR,Anand SS,et al.Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.Circulation,2006,114:774-782.
• [20]Manoukian SV,Feit F,Mehran R,et al.Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes:an analysis from the ACUITY Trial.J Am Coll Cardiol,2007,49:1362-1368.
• [21]Rao SV,O'Grady K,Pieper KS,et al.Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.Am J Cardiol,2005,96:1200-1206.
• [22]Rao SV,Eikelboom JA,Granger CB,et al.Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes.Eur Heart J,2007,28:1193-1204.
• [23]Doyle BJ,Rihal CS,Gastineau DA,et al.Bleeding,blood transfusion,and increased mortality after percutaneous coronary intervention:implications for contemporary practice.J Am Coll Cardiol,2009,53:2019-2127.
• [24]胡舜英,陈韵岱.ST段抬高心肌梗死抗栓治疗及出血问题.中国介入心脏病学杂志,2014,22:592-598.